Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Autologous CD34+ cells transfected with retroviral vector containing adenosine deaminase gene

EU orphan designation number: EU/3/05/313   
Active ingredient: Autologous CD34+ cells transfected with retroviral vector containing adenosine deaminase gene
Indication: Treatment of severe combined immunodeficiency (SCID) due to adenosine deaminase (ADA) deficiency
Sponsor: GlaxoSmithKline Trading Services Limited
Currabinny, Carrigaline, County Cork, Ireland

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
31/08/2005 Centralised Orphan - Designation EMEA/OD/053/05 (2005)3357 of 26/08/2005
02/12/2009 Other procedure
24/06/2011 Centralised Orphan - Transfer of orphan designation EMEA/OD/053/05/T/01 (2011)4557 of 21/06/2011
04/02/2014 Centralised Orphan - Change of address
01/08/2014 Centralised Orphan - Transfer of orphan designation EMA/OD/053/05/T/02 (2014)5573 of 30/07/2014